Schrödinger

131 articles about Schrödinger

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - September 18, 2023

  9/18/2023

  Schrödinger, Inc. reported that on September 14, 2023, the company granted non-statutory stock options to purchase 8,250 shares of the company’s common stock to six newly hired employees and restricted stock units with respect to 7,485 shares of the company’s common stock to 10 newly hired employees.

• Schrödinger to Present at Morgan Stanley Global Healthcare Conference

  9/5/2023

  Schrödinger today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - August 11, 2023

  8/11/2023

  Schrödinger, Inc. reported that on August 9, 2023, the company granted a non-statutory stock option to purchase 90,000 shares of the company’s common stock and restricted stock units with respect to 15,000 shares of the company’s common stock to the company’s newly appointed chief medical officer, Margaret Dugan, M.D. As previously announced, Dr. Dugan joined the company on July 31, 2023.

• Schrödinger Reports Second Quarter 2023 Financial Results

  8/2/2023

  Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the quarter ended on June 30, 2023.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 20, 2023

  7/20/2023

  Schrödinger, Inc. today reported that on July 14, 2023, the company granted (i) non-statutory stock options to purchase 10,250 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 6,225 shares of the company’s common stock to nine newly hired employees.

• Schrödinger to Announce Second Quarter 2023 Financial Results on August 2

  7/19/2023

  Schrödinger will report its second quarter 2023 financial results on Wednesday, August 2, 2023, after the financial markets close.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)-June 22, 2023

  6/22/2023

  Schrödinger, Inc. today reported that on June 16, 2023, the company granted (i) non-statutory stock options to purchase 14,325 shares of the company’s common stock to 11 newly hired employees and (ii) restricted stock units (RSUs) with respect to 11,138 shares of the company’s common stock to 11 newly hired employees.

• Schrödinger to Present at Goldman Sachs 44th Annual Global Healthcare Conference

  6/1/2023

  Schrödinger today announced that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference.

• Schrödinger to Present at Jefferies Global Biopharma Conference

  5/26/2023

  Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 25, 2023

  5/25/2023

  Schrödinger, Inc. reported that on May 19, 2023, the company granted non-statutory stock options to purchase 7,660 shares of the company’s common stock to five newly hired employees and restricted stock units with respect to 1,988 shares of the company’s common stock to two newly hired employees.

• Schrödinger Reports Strong First Quarter 2023 Financial Results

  5/4/2023

  Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the first quarter ended March 31, 2023.

• Schrödinger Publishes Inaugural Corporate Sustainability Report

  4/27/2023

  Schrödinger, Inc. today published its inaugural Corporate Sustainability Report.

• Schrödinger to Announce First Quarter 2023 Financial Results on May 4

  4/20/2023

  Schrödinger will report its first quarter 2023 financial results on Thursday, May 4, 2023, after the financial markets close.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 19, 2023

  4/19/2023

  Schrödinger, Inc. today reported that on April 14, 2023, the company granted (i) a non-statutory stock option to purchase 2,400 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSU) with respect to 1,800 shares of the company’s common stock to one newly hired employee.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 22, 2023

  3/22/2023

  Schrödinger, Inc. today reported that on March 19, 2023, the company granted non-statutory stock options to purchase an aggregate of 32,700 shares of the company’s common stock to 10 newly hired employees, including two newly hired employees based outside of the United States.

• Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results

  2/28/2023

  Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided its financial outlook for 2023.

• Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 17, 2023

  2/17/2023

  Schrödinger, Inc. reported that on February 15, 2023, the company granted non-statutory stock options to purchase an aggregate of 45,600 shares of the company’s common stock to 11 newly hired employees, including two newly hired employees based outside of the United States.

• Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda

  2/14/2023

  Schrödinger Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported the receipt of an $111.3 million cash distribution from Nimbus Therapeutics, LLC (Nimbus) in connection with Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

• Schrödinger to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 28

  2/13/2023

  Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2022 financial results on Tuesday, February 28, 2023, after the financial markets close.

• Schrödinger to Present at SVB Securities Global Biopharma Conference

  1/31/2023

  Schrödinger today announced that management will participate in the SVB Securities Global Biopharma Conference and will give a presentation on Tuesday, February 14, 2023, at 1:00 p.m. ET.